Safety assessment of liver-targeted hydrodynamic gene delivery in dogs

PLoS One. 2014 Sep 24;9(9):e107203. doi: 10.1371/journal.pone.0107203. eCollection 2014.

Abstract

Evidence in support of safety of a gene delivery procedure is essential toward gene therapy. Previous studies using the hydrodynamics-based procedure primarily focus on gene delivery efficiency or gene function analysis in mice. The current study focuses on an assessment of the safety of computer-controlled and liver-targeted hydrodynamic gene delivery in dogs as the first step toward hydrodynamic gene therapy in clinic. We demonstrate that the impacts of the hydrodynamic procedure were limited in the injected region and the influences were transient. Histological examination and the hepatic microcirculation measurement using reflectance spectrophotometry reveal that the liver-specific impact of the procedure involves a transient expansion of the liver sinusoids. No systemic damage or toxicity was observed. Physiological parameters, including electrocardiogram, heart rate, blood pressure, oxygen saturation, and body temperature, remained in normal ranges during and after hydrodynamic injection. Body weight was also examined to assess the long-term effects of the procedure in animals who underwent 3 hydrodynamic injections in 6 weeks with 2-week time interval in between. Serum biochemistry analysis showed a transient increase in liver enzymes and a few cytokines upon injection. These results demonstrate that image-guided, liver-specific hydrodynamic gene delivery is safe.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Chemokine CCL2 / blood
  • Dogs
  • Electrocardiography
  • Gene Transfer Techniques*
  • Genetic Therapy / adverse effects
  • Genetic Therapy / methods*
  • Hydrodynamics*
  • Injections / adverse effects
  • Injections / methods
  • Interleukin-10 / blood
  • Interleukin-6 / blood
  • Liver / blood supply
  • Liver / metabolism*
  • Liver Circulation
  • Monitoring, Physiologic
  • Reproducibility of Results
  • Risk Assessment
  • Tumor Necrosis Factor-alpha / blood

Substances

  • Chemokine CCL2
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Interleukin-10